At the news
? BULLISHIMPACT 7/10 PRESS-RELEASE filed Jun 16, 2026 at 08:02 ET
Outlook Therapeutics announced FDA acceptance of its resubmitted BLA for ONS-5010/LYTENAVA (bevacizumab-vikg) for wet AMD as a Class 1 review with a PDUFA target date of July 29, 2026. The company has initiated pre-launch activities, and approval would make it the first FDA-approved ophthalmic formulation of bevacizumab with standardized manufacturing and labeling. This is a major regulatory milestone for a $162M market-cap biotech with a single primary asset.
- FDA accepted resubmitted BLA for ONS-5010/LYTENAVA as Class 1 review
- PDUFA target action date set for July 29, 2026
- ONS-5010/LYTENAVA already has EU and UK marketing authorization for wet AMD
- Company has initiated pre-launch activities in anticipation of potential approval
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access